Antios Therapeutics Initiates First-in-Human Phase I Study of ATI-2173
Emory, collaborators testing antiviral drug as potential treatment for coronaviruses
New drug forces flu virus into ‘error catastrophe,’ overwhelming it with mutations
The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal Venezuelan equine encephalitis virus infection.
Drug Innovation Ventures at Emory (DRIVE) and Antios Therapeutics announce license for hepatitis B drug
What is Drug Innovation Ventures at Emory?
Georgia Bio honors Emory drug innovator with Georgia Bio Community Award
NPR’s Closer look examines DRIVE and EIDD
DRIVE CEO George Painter hiking in Death Valley
DRIVE founder Dennis Liotta discusses drugs for neglected diseases at TEDx Geneva